PBM Conflict Of Interest Study May Affect Their Role Under Medicare Rx
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress may revise the role of pharmacy benefit managers under the Medicare drug benefit based on the outcome of a Federal Trade Commission study, Sen. Michael Enzi (R-Wyo.) said
You may also be interested in...
CMS “Staffs Up” For Medicare Rx; McClellan Looks To PBM Execs
The agency would like experts who can be “loaned” from industry to prepare for implementation of the full drug benefit. The CMS head is also bringing in a number of his former FDA colleagues, including Economic Advisor Tomas Philipson.
PBM Conflict Of Interest Study Begins: FTC Contacting 20 PBMs, Pharmacies
The Federal Trade Commission will study whether using a PBM-owned mail order pharmacy costs more than using a non-PBM mail order or retail pharmacy. The study was mandated by the Medicare Rx law.
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.